Código QR

Development of a 2′,4′-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo

Recent advances in RNA interference (RNAi)-based drug development have partially allowed systemic administration of these agents in vivo with promising therapeutic effects. However, before chemically modified small-interfering RNAs (siRNAs) can be applied clinically, their in vivo effects should be...

Descrición completa

Gardado en:
Principais autores: Shunsuke Wada, Satoshi Obika, Masa-Aki Shibata, Tsuyoshi Yamamoto, Moeka Nakatani, Tetsuji Yamaoka, Hidetaka Torigoe, Mariko Harada-Shiba
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2012-01-01
Series:Molecular Therapy: Nucleic Acids
Assuntos:
siRNA
2′4′-BNA/LNA
chemical modification
dyslipidemia
innate immune response
Acceso en liña:http://www.sciencedirect.com/science/article/pii/S2162253116300993
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares